Enable JavaScript to visit this website.

What is XELJANZ/XELJANZ XR?

Quick Facts

Psoriatic arthritis could make it difficult to get in and out of bed, run errands, get dressed, and complete some other common daily activities. XELJANZ XR may be used to treat adults with active psoriatic arthritis in which methotrexate or other similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well. For the treatment of psoriatic arthritis, XELJANZ/XELJANZ XR is taken in combination with methotrexate, sulfasalazine, or leflunomide. Click the tabs below to learn more about XELJANZ XR.

Vertical Tabs

Quick Facts

Psoriatic arthritis could make it difficult to get in and out of bed, run errands, get dressed, and complete some other common daily activities. XELJANZ XR may be used to treat adults with active psoriatic arthritis in which methotrexate or other similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well. For the treatment of psoriatic arthritis, XELJANZ/XELJANZ XR is taken in combination with methotrexate, sulfasalazine, or leflunomide. Click the tabs below to learn more about XELJANZ XR.

Adult patients with active psoriatic arthritis can talk to their doctor about XELJANZ XR, a once-daily pill. XELJANZ XR is taken with a nonbiologic DMARD like methotrexate, and it is not an injection or an infusion—it's an UNJECTIONTM.

If you’re not getting enough relief of joint pain and swelling with a treatment like methotrexate alone, adding XELJANZ XR could help. If you’ve tried a biologic DMARD and it didn’t work well enough, starting on XELJANZ XR plus a nonbiologic DMARD may be an option. Regardless of where you are in your treatment, ask your doctor about XELJANZ XR.

Proven to provide rapid symptom relief, XELJANZ XR can reduce psoriatic arthritis joint pain and swelling in as early as 2 weeks. For some, it may take 3 to 6 months. Individual results may vary.

XELJANZ XR can help adults with active psoriatic arthritis improve their ability to complete certain daily activities, such as getting in and out of bed, running errands, getting dressed, and going on a walk.

XELJANZ/XELJANZ XR can lower the ability of your immune system to fight infections. Some people can have serious infections while taking XELJANZ/XELJANZ XR, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Learn more about the most important information you should know about XELJANZ/XELJANZ XR.

  • Increased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of XELJANZ/​XELJANZ XR.
  • Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of XELJANZ/​XELJANZ XR.
    • Stop taking XELJANZ/ ​XELJANZ XR and tell your healthcare provider right away if you have any signs and symptoms of a blood clot such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
  • The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is XELJANZ 5 mg twice daily or XELJANZ XR 11 mg one time each day.

The easy-to-open XELJANZ bottle cap has received an Arthritis Foundation Ease-of-Use Commendation.

The Arthritis Foundation’s Ease-of-Use Commendation recognizes products, such as the XELJANZ bottle cap, proven to make life easier for people who have arthritis and other physical limitations.

Common side effects of XELJANZ/​XELJANZ XR include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis), and high blood pressure (hypertension). XELJANZ/​XELJANZ XR may also cause serious side effects. Learn more about the most important information you should know about XELJANZ/​XELJANZ XR.

How It Works

WANT TO KNOW THE DIFFERENCE BETWEEN XELJANZ AND XELJANZ XR? FIND OUT HERE.

XELJANZ XR is the first and only Janus kinase (JAK) inhibitor approved for adults with active psoriatic arthritis. As a JAK inhibitor, XELJANZ XR works to disrupt cell activities believed to play a role in inflammation associated with psoriatic arthritis.

Select Milestones

In 2012, XELJANZ was approved for adults with moderate to severe rheumatoid arthritis (RA).
In 2017, XELJANZ/XELJANZ XR was approved to treat adults with active psoriatic arthritis (PsA).

See how XELJANZ has evolved through the years.

1994

Pfizer identifies JAK enzymes as potential drug targets

2002

1st clinical trial with humans launches clinical-development program

2012

XELJANZ, a twice-daily pill, is approved for adults with moderate to severe rheumatoid arthritis

2016

XELJANZ XR, a once-daily pill, becomes available to treat adults with moderate to severe rheumatoid arthritis

2017

XELJANZ/XELJANZ XR is approved for adults with active psoriatic arthritis

Clinical Trial Results

REQUEST MORE INFO ABOUT XELJANZ/XELJANZ XR.